ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 520,05
0,22%
Dow Jones
38 589,16
-0,15%
DAX
18 037,11
0,09%
Brent Oil
82,315
0,23%
Bitcoin
66 053,86
-0,88%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aurinia Pharmaceuticals Inc (AUPH)

  7. Aurinia Pharmaceuticals Inc (AUPH) Actualités

AUPH

Aurinia Pharmaceuticals (AUPH)

Aurinia Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AUPH
DateHeureSourceTitreSymboleSociété
14/06/202423h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUPHAurinia Pharmaceuticals Inc
14/06/202418h16Business WireAurinia Announces 2024 Annual General Meeting ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
05/06/202412h00Business WireAurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
04/06/202423h30Business WireAurinia Addresses Dubious Proposals Put Forth by Lucien SelceNASDAQ:AUPHAurinia Pharmaceuticals Inc
04/06/202423h25Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AUPHAurinia Pharmaceuticals Inc
04/06/202400h30Business WireAurinia Provides Update on Proxy StatementNASDAQ:AUPHAurinia Pharmaceuticals Inc
30/05/202412h00Business WireAurinia Will Attend 2024 Jefferies Global Healthcare ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
22/05/202422h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
14/05/202412h00Business WireAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
09/05/202412h00Business WireAurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
07/05/202412h00Business WireAurinia Will Attend 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
02/05/202412h00Business WireAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
01/05/202412h00Business WireAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness MonthNASDAQ:AUPHAurinia Pharmaceuticals Inc
30/04/202412h00Business WireThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
16/04/202416h48Business WireUPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
15/04/202412h00Business WireAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
09/04/202412h00Business WireAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
29/02/202414h30Business WireAurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
27/02/202414h30Business WireAurinia to Participate in Upcoming Investor Healthcare ConferencesNASDAQ:AUPHAurinia Pharmaceuticals Inc
22/02/202422h19Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202412h16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202412h00Business WireAurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder ValueNASDAQ:AUPHAurinia Pharmaceuticals Inc
14/02/202421h27Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AUPHAurinia Pharmaceuticals Inc
05/02/202414h30Business WireAurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
05/01/202412h00Business WireAurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
20/12/202312h00Business WireAurinia Submits IND Application to US Food & Drug Administration for AUR 200NASDAQ:AUPHAurinia Pharmaceuticals Inc
13/11/202312h00Business WireAurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in JapanNASDAQ:AUPHAurinia Pharmaceuticals Inc
07/11/202316h30Business WireAurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023NASDAQ:AUPHAurinia Pharmaceuticals Inc
02/11/202323h00Business WireAurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus NephritisNASDAQ:AUPHAurinia Pharmaceuticals Inc
02/11/202311h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AUPHAurinia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AUPH

Dernières Valeurs Consultées

NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
EU
VIV
Vivendi
EU
PX1
CAC 40
NYSE
NKE
Nike
NASDAQ
AAPL
Apple
EU
GLE
Societe Generale
EU
PX4
SBF 120
EU
BEL20
Bel 20
EU
MC
Lvmh Moet Hennessy Louis...
USI
USTECH100
US Tech 100
EU
AI
Air Liquide
NASDAQ
GOOGL
Alphabet
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés